Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.84
Dollar change
-0.04
Percentage change
-1.39
%
IndexRUT P/E4.03 EPS (ttm)0.70 Insider Own29.83% Shs Outstand67.71M Perf Week-1.05%
Market Cap192.50M Forward P/E- EPS next Y-1.09 Insider Trans-0.14% Shs Float47.57M Perf Month-85.49%
Income49.27M PEG- EPS next Q-0.00 Inst Own89.42% Short Float10.70% Perf Quarter-80.47%
Sales380.79M P/S0.51 EPS this Y-283.95% Inst Trans32.53% Short Ratio1.74 Perf Half Y-84.81%
Book/sh6.40 P/B0.44 EPS next Y15.49% ROA10.84% Short Interest5.09M Perf Year-90.69%
Cash/sh5.48 P/C0.52 EPS next 5Y- ROE12.73% 52W Range2.67 - 31.77 Perf YTD-80.71%
Dividend Est.- P/FCF18.02 EPS past 5Y- ROI11.32% 52W High-91.06% Beta-0.92
Dividend TTM- Quick Ratio5.20 Sales past 5Y2300.59% Gross Margin93.03% 52W Low6.37% ATR (14)0.89
Dividend Ex-Date- Current Ratio5.66 EPS Y/Y TTM130.51% Oper. Margin10.19% RSI (14)21.43 Volatility6.14% 10.04%
Employees384 Debt/Eq0.01 Sales Y/Y TTM1612.94% Profit Margin12.94% Recom2.50 Target Price5.14
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q110.48% Payout0.00% Rel Volume0.64 Prev Close2.88
Sales Surprise1.39% EPS Surprise-69.27% Sales Q/Q395.54% EarningsFeb 22 BMO Avg Volume2.92M Price2.84
SMA20-63.76% SMA50-77.59% SMA200-83.40% Trades Volume1,875,247 Change-1.39%
Date Action Analyst Rating Change Price Target Change
Mar-18-24Downgrade Mizuho Buy → Neutral $32 → $4
Mar-11-24Downgrade Robert W. Baird Outperform → Neutral $37 → $4
Mar-11-24Downgrade Leerink Partners Outperform → Market Perform $27 → $4
Mar-08-24Downgrade Goldman Buy → Neutral
Mar-08-24Downgrade Evercore ISI Outperform → In-line
Jan-03-24Initiated Robert W. Baird Outperform $37
Dec-12-23Initiated Deutsche Bank Buy $36
Jul-24-23Upgrade Goldman Neutral → Buy $45 → $49
Mar-31-23Initiated Mizuho Buy $52
Jan-05-23Initiated BofA Securities Buy $50
Mar-27-24 07:36AM
Mar-25-24 02:33PM
Mar-14-24 06:49PM
09:00AM
Mar-13-24 10:00AM
09:03AM Loading…
09:03AM
Mar-12-24 07:55AM
Mar-11-24 12:34PM
07:45AM
Mar-10-24 08:00AM
Mar-08-24 06:27PM
04:05PM
11:30AM
10:20AM
10:12AM
09:38AM Loading…
09:38AM
09:26AM
07:07AM
07:00AM
02:05AM
Feb-27-24 05:45AM
Feb-26-24 11:39AM
Feb-25-24 06:30AM
Feb-23-24 04:05PM
10:30AM
10:10AM
09:00AM
05:45AM
Feb-22-24 06:57PM
04:10PM
08:15AM Loading…
08:15AM
07:35AM
07:00AM
Feb-20-24 05:45AM
Feb-19-24 12:40PM
Feb-15-24 04:05PM
02:13PM
09:00AM
Feb-13-24 09:16PM
12:58PM
Feb-12-24 08:09PM
11:09AM
Feb-08-24 09:00AM
Jan-26-24 03:57PM
Jan-21-24 01:16PM
Jan-14-24 12:54PM
Jan-05-24 05:34AM
Dec-26-23 07:02PM
08:48AM
Dec-22-23 09:00AM
Dec-11-23 08:36AM
Dec-04-23 09:00AM
Nov-29-23 05:15PM
Nov-28-23 08:48AM
07:00AM
Nov-27-23 09:00AM
Nov-21-23 09:00AM
Nov-12-23 11:59AM
Nov-10-23 12:26AM
Nov-09-23 05:04PM
12:12PM
08:05AM
07:00AM
Nov-04-23 12:16PM
Nov-02-23 10:00AM
09:00AM
Oct-19-23 09:00AM
Oct-18-23 08:30AM
Oct-13-23 08:26AM
07:55AM
07:45AM
Oct-11-23 08:07AM
Oct-10-23 09:45AM
09:12AM
Oct-05-23 05:26PM
Oct-02-23 09:00AM
Sep-29-23 12:43PM
02:54AM
Sep-20-23 09:02AM
Sep-05-23 09:00AM
Aug-28-23 11:53PM
Aug-14-23 05:38AM
Aug-13-23 08:26AM
Aug-11-23 08:47AM
Aug-10-23 05:15PM
04:01PM
Aug-03-23 04:05PM
Jul-28-23 12:56PM
09:19AM
Jul-24-23 12:17PM
Jul-19-23 05:00AM
Jul-12-23 09:00AM
Jun-27-23 10:57AM
Jun-26-23 10:36AM
Jun-23-23 11:27AM
08:14AM
Jun-15-23 09:00AM
Jun-13-23 11:15AM
Jun-12-23 06:53AM
Jun-06-23 09:00AM
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klee Justin B.Co-Chief Executive OfficerMar 05 '24Sale18.734,13577,4402,959,308Mar 07 04:05 PM
Cohen Joshua BCo-Chief Executive OfficerMar 05 '24Sale18.734,13577,4403,023,002Mar 07 04:05 PM
FRATES JAMES MChief Financial OfficerMar 05 '24Sale18.731,79233,560134,784Mar 07 04:05 PM
Mazzariello GinaChief Legal OfficerMar 05 '24Sale18.731,54028,84181,372Mar 07 04:05 PM
Mazzariello GinaChief Legal OfficerFeb 23 '24Sale18.762,83853,23146,245Feb 27 05:59 PM
Klee Justin B.Co-Chief Executive OfficerJan 09 '24Sale16.335,84195,3722,836,776Jan 11 05:11 PM
Cohen Joshua BCo-Chief Executive OfficerJan 09 '24Sale16.335,84195,3722,900,470Jan 11 05:10 PM
Yeramian Patrick DChief Medical OfficerJan 09 '24Sale16.332,81245,915205,605Jan 11 05:04 PM
FRATES JAMES MChief Financial OfficerJan 09 '24Sale16.332,71644,347112,035Jan 11 05:11 PM
Olinger MargaretChief Commercial OfficerDec 27 '23Option Exercise0.3725,0009,250276,108Dec 29 04:07 PM
Firestone KarenDirectorDec 15 '23Buy14.974,00059,8805,000Dec 19 04:37 PM
Cohen Joshua BCo-Chief Executive OfficerNov 16 '23Option Exercise1.5763,694100,0002,906,311Nov 20 08:20 PM
FRATES JAMES MChief Financial OfficerAug 23 '23Option Exercise6.8818,165124,975106,341Aug 24 04:15 PM
Mazzariello GinaChief Legal OfficerAug 15 '23Sale20.886,164128,68649,083Aug 17 04:35 PM
Olinger MargaretChief Commercial OfficerJul 12 '23Option Exercise0.3720,0007,400251,108Jul 14 04:20 PM
FRATES JAMES MChief Financial OfficerMay 16 '23Option Exercise6.8832,500223,60088,176May 18 08:54 PM
FRATES JAMES MChief Financial OfficerMay 16 '23Sale26.9432,500875,45155,676May 18 08:54 PM
Yeramian Patrick DChief Medical OfficerMay 15 '23Option Exercise5.6811,96567,991220,382May 17 04:58 PM
Yeramian Patrick DChief Medical OfficerMay 15 '23Sale29.0311,965347,358208,417May 17 04:58 PM
Yeramian Patrick DChief Medical OfficerApr 17 '23Option Exercise0.9949,57949,058257,996Apr 19 07:45 PM
Yeramian Patrick DChief Medical OfficerApr 17 '23Sale30.5449,5791,513,942208,417Apr 19 07:45 PM
Morningside Venture Investment10% OwnerMar 29 '23Sale30.4529,048884,5126,997,302Mar 31 04:05 PM